USE OF THYMIDINE AND DEOXYCYTIDINE AS A COMBINED NUTRITIONAL PRODUCT FOR THE TREATMENT OF TK2-ASSOCIATED MITOCHONDRIAL MYOPATHY Russian patent published in 2024 - IPC A61K31/7068 A61K31/7064 A61K31/513 A61K47/40 A61P43/00 

FIELD: pharmaceuticals and food industry.

SUBSTANCE: therapeutic nutrition for pathogenetic therapy of TK2-associated mitochondrial myopathy. The use of thymidine and deoxycytidine as a combined therapeutic food product for the treatment of TK2-associated mitochondrial myopathy, which includes thymidine in an amount of 200 to 800 mg, deoxycytidine in an amount of 200 to 800 mg and maltodextrin in an amount of 69 to 276 mg.

EFFECT: above-described use of thymidine and deoxycytidine with maltodextrin as a combined medical nutrition product is effective for the treatment of TK2-associated mitochondrial myopathy, ensures the absence of adverse events and undesirable reactions, such as deviations from the norm in biochemical parameters of the liver and kidneys; no diarrhea; the presence of statistically significant differences in the average score of the HFMSE scale, reflecting gross motor skills; statistically significant differences in the average score of all indicators of the HINE-2 Scale; statistically significant differences in the average score of the MRC Scale, which reflects muscle strength; differences in the average need for respiratory support (NIV) before and after use of the product, compared with the use of deoxynucleosides in the form of chemicals; the product also has good organoleptic properties and a pleasant taste.

2 cl, 13 tbl, 2 ex